TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC 50 value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A , FER , PTK2 and RPS6KA1 with IC 50 values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib ( HY-15656 ) and the Cereblon ligand of Pomalidomide ( HY-10984 ). (Pink: Anaplastic lymphoma kinase (ALK) ligand ( HY-15656 ); Blue: Cereblon ligand ( HY-41547 ); Black: linker).
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.